Legend Biotech Management

Management Kriterienprüfungen 2/4

Legend Biotech's CEO ist Ying Huang , ernannt in Sep 2020, hat eine Amtszeit von 3.75 Jahren. besitzt direkt 0.035% der Aktien des Unternehmens, im Wert von $2.67M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.1 Jahre bzw. 3 Jahre.

Wichtige Informationen

Ying Huang

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	3.8yrs
Eigentum des Geschäftsführers	0.04%
Durchschnittliche Amtszeit des Managements	2.1yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3yrs

Jüngste Management Updates

Recent updates

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

May 14

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

May 13

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Dec 14

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Sep 27

Legend Biotech stock slides on proposed ADS offering

Jul 25

Legend Biotech ends Phase 1 trial for lymphoma candidate

Jul 07

News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Jun 05

Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

May 14

Here's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Full-Year Results

Mar 22

Legend Biotech: Carvykti Approval Makes For A Buy Opportunity

Mar 04

Legend Biotech Corporation (NASDAQ:LEGN) Analysts Are More Bearish Than They Used To Be

Mar 03

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Dec 30

Calculating The Intrinsic Value Of Legend Biotech Corporation (NASDAQ:LEGN)

Nov 22

Is Legend Biotech (NASDAQ:LEGN) Using Debt Sensibly?

Aug 26

Analysts Have Just Cut Their Legend Biotech Corporation (NASDAQ:LEGN) Revenue Estimates By 18%

Jun 11

Geschäftsführer

Ying Huang (51 yo)

3.8yrs

Amtszeit

Dr. Ying Huang, Ph D., had been Chief Financial Officer of Legend Biotech Corporation since July 2019 until May 09, 2022 and was its Interim Chief Executive Officer since September 21, 2020 until November...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ying Huang	CEO & Director	3.8yrs	keine Daten	0.035% $ 2.6m
Lori Macomber	Chief Financial Officer	2.1yrs	keine Daten	0.0031% $ 228.0k
Doug Wallace	Vice President of Global Operations	less than a year	keine Daten	keine Daten
Guowei Fang	Chief Scientific Officer & Head of Business Development	no data	keine Daten	keine Daten
Joanne Choi	Senior Manager of Investor Relations	no data	keine Daten	keine Daten
James Pepin	General Counsel	less than a year	keine Daten	keine Daten
Deborah Wong	Executive Director of Strategic Marketing & Corporate Communications	no data	keine Daten	keine Daten
Elaine Qian	VP & Global Head of Human Resources	1.2yrs	keine Daten	keine Daten
Yuhong Qiu	Senior Vice President of Global Regulatory Affairs	2.4yrs	keine Daten	keine Daten
Steven Gavel	Senior Vice President of Commercial Development	2.4yrs	keine Daten	keine Daten
Alan Kick	Senior Vice President of Global Quality	2.4yrs	keine Daten	keine Daten
Mythili Koneru	Chief Medical Officer	1.2yrs	keine Daten	keine Daten

2.1yrs

Durchschnittliche Betriebszugehörigkeit

51yo

Durchschnittliches Alter

Erfahrenes Management: LEGNDas Führungsteam des Unternehmens gilt als erfahren (2.1 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ying Huang	CEO & Director	2.5yrs	keine Daten	0.035% $ 2.6m
John M. Maraganore	Member of Strategic Advisory Board	1.2yrs	keine Daten	keine Daten
Li Zhu	Non-Independent Director	3.6yrs	keine Daten	keine Daten
Corazon Sanders	Independent Director	4.1yrs	keine Daten	0.011% $ 777.0k
Xiaohui Ji	Independent Director	4.1yrs	keine Daten	0.0050% $ 372.6k
Tomas Heyman	Independent Director	1.8yrs	keine Daten	0.0011% $ 82.6k
Fangliang Zhang	Independent Chairman	1.8yrs	keine Daten	0% $ 0
Ye Wang	Director	9.1yrs	keine Daten	0% $ 0
Michel Vounatsos	Member of Strategic Advisory Board	1.2yrs	keine Daten	keine Daten
Wai Man Yau	Independent Director	4.1yrs	keine Daten	0.0010% $ 76.0k
Patrick Casey	Independent Director	3.5yrs	keine Daten	0.0069% $ 512.8k
Li Mao	Independent Director	1.8yrs	keine Daten	0.0019% $ 140.2k

3.0yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrener Vorstand: LEGNDie Vorstandsmitglieder gelten als erfahren (3 Jahre durchschnittliche Amtszeit).

Legend Biotech Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Legend Biotech Corporation, Annual General Meeting, Sep 21, 2023

CEO & Director notifies of intention to sell stock

Recent updates

Legend Biotech Corporation Shares Data on the Earlier Use to Date of CARVYKTI in the Treatment of Multiple Myeloma and Important Subgroup Analyses At ASCO and EHA

Legend Biotech Corporation to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHA

Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Some Shareholders Feeling Restless Over Legend Biotech Corporation's (NASDAQ:LEGN) P/S Ratio

Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Legend Biotech Corporation Announces CARVYKTI (Ciltacabtagene Autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade)

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

CEO & Director notifies of intention to sell stock

Legend Biotech: Solid Traction With Carvykti Rollout

Legend Biotech Provides Update on U.S. FDA and EMA Applications for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel) in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma

Legend Biotech Corporation's (NASDAQ:LEGN) Share Price Not Quite Adding Up

Legend Biotech Announces U.S. FDA Label Update for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel)

Legend Biotech Corporation Announces Patient-Reported Outcome (Pro) Data from the Phase 3 CARTITUDE-4 Study

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Legend Biotech (NASDAQ:LEGN) A Risky Investment?

CEO & Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Legend Biotech Corporation, Annual General Meeting, Sep 21, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 11%

Legend Biotech Corporation Announces Submission of Supplemental Application to U.S. FDA for Expanded Use of CARVYKTI® (Ciltacabtagene Autoleucel)

Legend Biotech Corporation Announces Results from the Phase 3 CARTITUDE-4 Study

CEO & Director notifies of intention to sell stock

Legend Biotech Corporation Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI®? (Ciltacabtagene Autoleucel)

Price target increased by 7.7% to US$79.70

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Legend Biotech Corporation to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350 million.

Chief Financial Officer notifies of intention to sell stock

Is Legend Biotech (NASDAQ:LEGN) Weighed On By Its Debt Load?

Independent Director notifies of intention to sell stock

Full year 2022 earnings: Revenues miss analyst expectations

Second quarter 2022 earnings released: US$1.25 loss per share (vs US$0.66 loss in 2Q 2021)

Legend Biotech Corporation Announces Research and Development Update

Legend Biotech Receives Notification of Delinquency from The Nasdaq Stock Market LLC

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

An Intrinsic Calculation For Legend Biotech Corporation (NASDAQ:LEGN) Suggests It's 44% Undervalued

Chief Financial Officer notifies of intention to sell stock

Legend Biotech Corporation Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

High number of new and inexperienced directors

Legend Biotech Corporation Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022

Legend Biotech Corporation Elects Philip Yau as Director

Consensus forecasts updated

Legend Biotech Corporation Announces that CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Legend Biotech wins approval of Carvykti for multiple myeloma in Japan

Legend Biotech Corporation, Annual General Meeting, Oct 14, 2022

Legend Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Legend Biotech Corporation Announces Board Changes

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million.

Legend Biotech Corporation has completed a Follow-on Equity Offering in the amount of $350.02 million.

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Legend Biotech stock slides on proposed ADS offering

Legend Biotech Corporation Legend Biotech Announces Termination of Its Phase 1 Clinical Trial Under Investigational New Drug Application for LB1901

Legend Biotech ends Phase 1 trial for lymphoma candidate

CEO & Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 32%

News Flash: Analysts Just Made A Notable Upgrade To Their Legend Biotech Corporation (NASDAQ:LEGN) Forecasts

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Across Lines of Therapy in Patients with Multiple Myeloma

Legend Biotech Corporation Announces U.S. FDA Clearance of IND Application for Solid Tumor Car-T, Lb1908 for Relapsed or Refractory Gastric, Esophageal and Pancreatic Cancers

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

European Commission Grants Marketing Authorization to CARVYKTI of Legend Biotech Corporation

Legend Biotech (NASDAQ:LEGN) Has Debt But No Earnings; Should You Worry?

Legend Biotech Appoints Lori Macomber as Chief Financial Officer

High number of new and inexperienced directors

Legend Biotech Announces Executive Changes